Display options
Cite
Chue P. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat. 2007;3(1):13-39doi: 10.2147/nedt.2007.3.1.13.
Chue, P. (2007). Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatric disease and treatment, 3(1), 13-39. https://doi.org/10.2147/nedt.2007.3.1.13
Chue, Pierre. "Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic." Neuropsychiatric disease and treatment vol. 3,1 (2007): 13-39. doi: https://doi.org/10.2147/nedt.2007.3.1.13
Chue P. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat. 2007 Feb;3(1):13-39. doi: 10.2147/nedt.2007.3.1.13. PMID: 19300536; PMCID: PMC2654523.
Copy Download .nbib Format: NLM
Share it on

Neuropsychiatr Dis Treat. 2007 Feb;3(1):13-39. doi: 10.2147/nedt.2007.3.1.13.

Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.

Neuropsychiatric disease and treatment

Pierre Chue

Affiliations

  1. Department of Psychiatry University of Alberta, Edmonton, Alberta, Canada.

PMID: 19300536 PMCID: PMC2654523 DOI: 10.2147/nedt.2007.3.1.13

Abstract

OBJECTIVE: To review the pharmacokinetics, efficacy, safety, and cost-effectiveness of long-acting risperidone.

METHODS: Studies published between January 2000 and October 2006 evaluating the pharmacokinetics, efficacy, safety, and cost-effectiveness of long-acting risperidone were reviewed, as identified from literature searches using Medline and EMBASE. Abstracts and posters on long-acting risperidone presented at key psychiatry congresses and available in the public domain during this time period were also reviewed.

RESULTS: The unique pharmacokinetic profile of long-acting risperidone is derived from the encapsulation of risperidone in a glycolide/lactide matrix in the form of microspheres such that after a single intramuscular injection, significant plasma levels of the drug are achieved after week 3. Steady state, after repeated administration at 2-week intervals, is achieved after 3 injection cycles. Short- and long-term studies have demonstrated that long-acting risperidone (25, 37.5, or 50 mg) is both efficacious and well tolerated in a wide variety of patients with schizophrenia and related psychoses. Most patients can be switched from other oral and long-acting antipsychotic agents without compromising efficacy and safety. Long-acting risperidone may also reduce overall healthcare costs by decreasing rates of relapse and hospitalization.

CONCLUSION: The assured delivery of an atypical antipsychotic medication with long-acting risperidone has important implications for patient compliance, maintenance of stability, consistency of treatment, and improving patient outcomes including the achievement of remission.

Keywords: efficacy; long-acting injectable risperidone; pharmacoeconomics; pharmacokinetics; safety; schizophrenia

References

  1. N Engl J Med. 2005 Sep 22;353(12):1209-23 - PubMed
  2. Pharmacoeconomics. 2005;23 Suppl 1:1-2 - PubMed
  3. Hum Psychopharmacol. 2006 Aug;21(6):399-407 - PubMed
  4. J Clin Psychiatry. 2006 Aug;67(8):1310-1 - PubMed
  5. Am J Psychiatry. 2002 Jan;159(1):103-8 - PubMed
  6. Am J Psychiatry. 1994 Jun;151(6):825-35 - PubMed
  7. Cochrane Database Syst Rev. 2000;(2):CD001361 - PubMed
  8. Can J Psychiatry. 1993 Sep;38 Suppl 3:S80-8 - PubMed
  9. Int J Geriatr Psychiatry. 2004 Sep;19(9):898-905 - PubMed
  10. Int Clin Psychopharmacol. 2000 Jan;15(1):13-22 - PubMed
  11. Pharmacoeconomics. 2005;23 Suppl 1:75-89 - PubMed
  12. Pharmacoepidemiol Drug Saf. 2004 Nov;13(11):811-6 - PubMed
  13. J Psychopharmacol. 2005 Sep;19(5 Suppl):15-21 - PubMed
  14. Pharmacoeconomics. 2005;23 Suppl 1:62-74 - PubMed
  15. Hosp Community Psychiatry. 1990 Aug;41(8):892-7 - PubMed
  16. Eur Neuropsychopharmacol. 2005 Jan;15(1):111-7 - PubMed
  17. Br J Psychiatry Suppl. 1994 Nov;(25):18-21 - PubMed
  18. Psychiatr Prax. 2004 Apr;31(3):138-46 - PubMed
  19. J Clin Psychiatry. 2001 Nov;62(11):855-9 - PubMed
  20. J Clin Psychiatry. 1996 Aug;57(8):337-45 - PubMed
  21. J Psychopharmacol. 2005 Sep;19(5 Suppl):32-8 - PubMed
  22. J Clin Psychiatry. 2000;61 Suppl 8:43-9; discussion 50-1 - PubMed
  23. Int Clin Psychopharmacol. 2005 Jul;20(4):213-21 - PubMed
  24. Int Clin Psychopharmacol. 2002 May;17(3):135-40 - PubMed
  25. J Clin Psychiatry. 2004 Apr;65(4):531-6 - PubMed
  26. Biol Psychiatry. 1993 Feb 15;33(4):227-35 - PubMed
  27. Int J Neuropsychopharmacol. 2005 Mar;8(1):27-36 - PubMed
  28. J Psychopharmacol. 2005 Sep;19(5 Suppl):5-14 - PubMed
  29. Br J Psychiatry. 2001 Oct;179:300-7 - PubMed
  30. J Psychopharmacol. 2005 Sep;19(5 Suppl):22-31 - PubMed
  31. J Clin Psychiatry. 1999;60 Suppl 21:20-4 - PubMed
  32. Schizophr Res. 2005 Jan 1;72(2-3):249-58 - PubMed
  33. Schizophr Res. 2004 Sep 1;70(1):91-100 - PubMed
  34. Int Clin Psychopharmacol. 2005 Jul;20(4):207-12 - PubMed
  35. Eur Neuropsychopharmacol. 2007 Jan 15;17(2):138-44 - PubMed
  36. J Affect Disord. 2004 Dec;83(2-3):263-75 - PubMed
  37. Eur Neuropsychopharmacol. 1998 Feb;8(1):55-66 - PubMed
  38. Can J Psychiatry. 2006 Jul;51(8):531-9 - PubMed
  39. Drugs. 1994 May;47(5):741-73 - PubMed
  40. J Clin Psychiatry. 1986 May;47(5):247-8 - PubMed
  41. J Clin Psychiatry. 1984 May;45(5 Pt 2):50-9 - PubMed
  42. J Clin Psychiatry. 2002 Jan;63(1):9-14 - PubMed
  43. J Clin Psychiatry. 2003 Oct;64(10):1250-7 - PubMed
  44. Int Clin Psychopharmacol. 2000 Sep;15(5):245-55 - PubMed
  45. Curr Med Res Opin. 2005 Dec;21(12):2017-28 - PubMed
  46. Qual Life Res. 1999 Aug;8(5):417-26 - PubMed
  47. Br J Psychiatry. 2001 Oct;179:290-9 - PubMed
  48. Schizophr Res. 2005 Sep 15;77(2-3):129-39 - PubMed
  49. Am J Psychiatry. 2003 Jun;160(6):1125-32 - PubMed
  50. Acta Psychiatr Scand Suppl. 1994;382:28-32 - PubMed
  51. Arch Gen Psychiatry. 1999 Mar;56(3):241-7 - PubMed
  52. Am J Psychiatry. 2002 Jun;159(6):1018-28 - PubMed
  53. Acta Neuropsychiatr. 2004 Dec;16(6):301-13 - PubMed
  54. Int Clin Psychopharmacol. 2004 Jul;19(4):241-9 - PubMed
  55. Int Clin Psychopharmacol. 2001 Jan;16 Suppl 1:S1-8 - PubMed
  56. Br J Psychiatry. 1997 May;170:422-5 - PubMed
  57. J Clin Psychiatry. 2001 Jul;62(7):545-51 - PubMed
  58. Neuropsychopharmacology. 1996 Feb;14(2):111-23 - PubMed
  59. J Clin Psychiatry. 2004 Feb;65(2):267-72 - PubMed
  60. Am J Psychiatry. 2006 Mar;163(3):396-401 - PubMed
  61. Schizophr Bull. 1999;25(4):721-9 - PubMed
  62. Am J Psychiatry. 2005 Mar;162(3):441-9 - PubMed
  63. Br J Psychiatry. 2005 Aug;187:131-6 - PubMed
  64. CNS Drugs. 2004;18 Suppl 2:5-17; discussion 41-3 - PubMed
  65. J Clin Psychiatry. 1997 Dec;58(12):538-46 - PubMed
  66. Schizophr Res. 1999 Jan 4;35(1):51-68 - PubMed
  67. Int J Geriatr Psychiatry. 2000 Jun;15(6):506-14 - PubMed
  68. Pharmacoeconomics. 2005;23 Suppl 1:35-47 - PubMed
  69. J Clin Psychiatry. 2004 Aug;65(8):1076-83 - PubMed
  70. J Clin Psychiatry. 2004 Aug;65(8):1084-9 - PubMed
  71. Am J Psychiatry. 2000 Apr;157(4):514-20 - PubMed
  72. J Clin Psychiatry. 1999;60 Suppl 23:5-9 - PubMed
  73. Am J Psychiatry. 1999 Aug;156(8):1138-48 - PubMed
  74. Arch Gen Psychiatry. 1998 Mar;55(3):250-8 - PubMed
  75. Pharmacoeconomics. 2005;23 Suppl 1:49-61 - PubMed
  76. J Clin Psychiatry. 2003;64 Suppl 16:18-23 - PubMed
  77. J Clin Psychiatry. 2003;64 Suppl 16:41-6 - PubMed
  78. Ann Pharmacother. 1997 Nov;31(11):1360-9 - PubMed
  79. Eur Neuropsychopharmacol. 2002 Aug;12(4):305-10 - PubMed
  80. Psychiatr Serv. 2004 Sep;55(9):997-1005 - PubMed
  81. Acta Psychiatr Scand Suppl. 2000;(407):15-8 - PubMed
  82. Schizophr Bull. 1999;25(2):201-22 - PubMed
  83. Health Technol Assess. 2003;7(13):1-193 - PubMed
  84. Psychol Med. 2003 Jan;33(1):83-9 - PubMed
  85. J Clin Pharm Ther. 2000 Jun;25(3):197-220 - PubMed
  86. Drugs R D. 2005;6(3):129-37 - PubMed
  87. Pharmacopsychiatry. 1997 Mar;30(2):35-42 - PubMed
  88. Br J Psychiatry. 2004 Apr;184:346-51 - PubMed
  89. Int Clin Psychopharmacol. 2000 Nov;15(6):343-9 - PubMed
  90. Am J Psychiatry. 1999 Feb;156(2):286-93 - PubMed
  91. Acta Psychiatr Scand. 2000 Apr;101(4):323-9 - PubMed
  92. Schizophr Res. 2005 Sep 15;77(2-3):215-27 - PubMed
  93. J Clin Psychopharmacol. 1994 Jun;14(3):201-4 - PubMed
  94. Coll Antropol. 2003;27 Suppl 1:111-8 - PubMed
  95. BMJ. 2000 Dec 2;321(7273):1371-6 - PubMed
  96. Pharmacoeconomics. 1998 Jul;14(1):97-133 - PubMed
  97. Eur Psychiatry. 2004 Jun;19(4):219-25 - PubMed
  98. Int Clin Psychopharmacol. 2005 May;20(3):121-30 - PubMed
  99. Int Clin Psychopharmacol. 2004 Jul;19(4):229-32 - PubMed
  100. Drugs Today (Barc). 2004 May;40(5):445-64 - PubMed
  101. Br J Psychiatry. 1995 Jan;166(1):68-72 - PubMed
  102. Curr Med Res Opin. 2004 Sep;20(9):1357-63 - PubMed
  103. Int J Neuropsychopharmacol. 2005 Sep;8(3):427-38 - PubMed

Publication Types